BusinessVCANBIO USA and VCANBIO Center for Translational Biotechnology Launch in the United StatesBy Nasdaq OMXSep 8, 2016, 12:01 PM UTC
BusinessFate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell ImmunotherapiesBy Nasdaq OMXSep 7, 2016, 11:01 AM UTC
BusinessPeregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred StockBy Nasdaq OMXSep 6, 2016, 8:05 PM UTC
BusinessNational Comprehensive Cancer Network (NCCN) Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals’ Bavituximab in Multiple CancersBy Nasdaq OMXSep 6, 2016, 12:45 PM UTC
BusinessPreclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXApr 20, 2016, 12:05 PM UTC
BusinessAREVA Med Inaugurates Second Lead-212 Production FacilityBy Nasdaq OMXApr 13, 2016, 7:23 PM UTC
BusinessCidara Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 18, 2016, 11:30 AM UTC
BusinessPeregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent DevelopmentsBy Nasdaq OMXMar 9, 2016, 1:00 PM UTC
